Cyclotriazadisulfonamide (CADA) is a specific inhibitor of HIV entry that targets CD4. It functions by preventing the co-translational translocation of human CD4 (huCD4) into the endoplasmic reticulum (ER) lumen through a mechanism dependent on the signal peptide (SP).